Showing results (71-80 of 113) with videos related to

Sort By:
Pageof 12
Science (New York, N.Y.)|March 6, 2014
Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virusChasity D Andrews, William R Spreen, Hiroshi Mohri, et al.
AIDS and Behavior|July 27, 2017
Lessons for Patient Education Around Long-Acting Injectable PrEP: Findings from a Mixed-Method Study of Phase II Trial ParticipantsKathrine Meyers, Kristina Rodriguez, Atrina L Brill, et al.
The Journal of Infectious Diseases|June 9, 2019
Once-Weekly Oral Dosing of MK-8591 Protects Male Rhesus Macaques From Intrarectal Challenge With SHIV109CP3Martin Markowitz, Agegnehu Gettie, Leslie St Bernard, et al.
AIDS (London, England)|April 23, 2008
Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistanceLin Liu, Susanne May, Douglas D Richman, et al.
HIV Clinical Trials|November 18, 2018
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trialMiranda I Murray, Martin Markowitz, Ian Frank, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 30, 2006
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individualsMartin Markowitz, Javier O Morales-Ramirez, Bach-Yen Nguyen, et al.
AIDS (London, England)|October 21, 2006
Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacityJason D Barbour, Frederick M Hecht, Susan J Little, et al.
The Journal of Infectious Diseases|August 27, 2002
Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccinationMartin Markowitz, Xia Jin, Arlene Hurley, et al.
The Journal of Infectious Diseases|December 20, 2011
The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individualsChristine M Hogan, Victor Degruttola, Xin Sun, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 4, 2009
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infectionMartin Markowitz, Bach-Yen Nguyen, Eduardo Gotuzzo, et al.
Pageof 12